Calls for papers
-
Virpax Pharmaceuticals said that it has acquired exclusive North American rights to Nanomerics’ MMS019 nasal powder, which it calls a “high density molecular masking spray” and which is intended to block viruses from taking hold in… Read more . . .
-
The FDA has approved Lupin’s generic version of Teva’s ProAir HFA albuterol MDI for the treatment of asthma, the company said. Lupin said that it will manufacture the inhaler at its facility in Indore, India.… Read more . . .
-
Medical Developments International (MVP) has announced that it will buy back the European Union rights to its Penthrox methoxyflurane inhaler from Mundipharma for €3 million, plus a 5% royalty up to a maximum of €5… Read more . . .
-
Verona Pharma has announced the initiation of a Phase 2b trial of its ensifentrine MDI for the treatment of COPD in the UK, with results expected in the first half of 2021. In March 2020,… Read more . . .
-
According to Lannett, the company has signed an agreement with Chinese inhaled drug developer Respirent for exclusive rights to distribute Respirent’s generic version of GSK’s Flovent Diskus fluticasone propionate DPI, which is in early development.… Read more . . .
-
The FDA has accepted a supplemental NDA for United Therapeutics’s Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), the company said. In February 2020, United Therapeutics announced… Read more . . .
-
Danish pharma company Union Therapeutics has entered into an agreement with TFF Pharmaceuticals for an option to license TFF’s dry powder niclosamide, the companies announced. The deal includes potential inhaled and oral formulations of niclosamide… Read more . . .
-
Aerosol testing company Proveris Scientific has announced two new appointments: Joseph Werbeck rejoins the company as Senior Director of Technical Service and Mohamed Eldam joins Proveris as Applications Chemist. Werbeck, who will report to VP… Read more . . .
-
AstraZeneca has announced that the first doses of its FluMist Quadrivalent live intranasal flu vaccine for the 2020-2021 US influenza season have shipped. FluMist Quadrivalent is approved for use in children over the age of… Read more . . .
-
TFF Pharmaceuticals announced that the company has raised $25.9 million in a private placement, with the funds to be used to “to accelerate the expansion of the company’s internal development portfolio beyond its programs for… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA